D3 Bio
成陈 has worked in the medical field since 2010. 成 began their career as a Principal Physician at the Shanghai Jiaotong University Affiliated Shanghai Children's Medical Center. In 2016, they became a Medical Consultant/Medical Advisor at GenomiCare Biotechnology. From 2018 to 2021, they worked at BeiGene as a Senior Physician II, Senior Physician I, and Physician II. Currently, they are a Medical Director at D3 Bio.
成陈 attended Fudan University from 2003 to 2010, where they earned a Bachelor of Medicine degree in External Medicine.
This person is not in any teams
This person is not in any offices
D3 Bio
1 followers
D3 Bio is a globally focused biotechnology company focusing on developing and registration of innovative medicines in oncology and immunology. At D3 Bio, their new medicine development approach is fundamentally differentiated. They do not just only start with science in the lab. First, they pinpoint the greatest unmet patient and market needs – where existing standard-of-care approaches yield unsatisfactory clinical outcomes. Then they take those insights into lab to guide the identification of fit for purpose science and technology, and define their drug development path. D3 Bio R&D programs are also designed to create a structure, which would enable us to create a robust portfolio and identify assets carrying “back-bone” property for developing future therapies in multiple indications. Their portfolio will include assets from internal effort as well as assets in-licensed in pre-clinical or clinical-stage investigational compounds. This cycle of innovation is at the heart of D3 Bio. In fact, it underlies their name: Development leading to Discovery that then leads back to more Development, or D3 Bio.” D3 Bio is backed by a syndicate of world-class investors whose support underscores their belief in the promise of the Company. Major investors include Boyu Capital, Matrix Partners China, Sequoia Capital China, Temasek, and WuXi AppTec's Corporate Venture Fund.